胰岛素增敏剂对2型糖尿病大血管病变患者金属基质蛋白酶9的影响及意义(3)
 |
| 第1页 |
参见附件(1941KB，3页)。
[3]Lemaitre V,O'Byrne TK,Borczuk AC,et al.ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis[J].Ournal Of Clinical Investigation,2001,107(10):1227-1234.
[4]Oton MDA,Luna JGC,Fernandez EG,et al.LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus type 2 [J].Medicina Clinica,2009,132(3):98-101.
[5]LI AC,Brown KK,Silvest REMJ,et al. Peroxisome proliferator-activated receptor C-ligands inhibit development of atherosclerosis in LDL receptor dificient mice[J]. J Clin Invest,2000,106:523-531.
[6]Sidhu JS, Kaski JC. Peroxisomeproliferator activated receptor C : a potential therapeutic target in the management of ischaemic heart disease[J]. Heart,2001,86(5):255-258.
[7]Nissen Se,Wolskik. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [J]. N Engl JMed,2007,356(24):2457-2471.
[8]Home Pd,Pocock Sj,Beck Nielsen H,et al.Rosiglitaz one evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD ): a multicentre,randomised, open-label trial[J]. Lancet,2009,373 (9681):2125-2135 .
[9]Barid Study Group,Frye Rl,August P,et al.A randomized trial of therapies for type 2 diabetes and coronary artery disease[J]. N Engl JM ed,2009,360(24):2503-2515.
(收稿日期:2010-03-10)
您现在查看是摘要介绍页，详见PDF附件(1941KB，3页)。